Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — FY2025 Earnings Presentation
28 slides from Imricor Medical Systems's earnings presentation, Feb 25, 2026
Slide 1: FY 2025 Investor Presentation
FEBRUARY 25TH 2026 FY 2025 Investor Presentation Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
FEBRUARY 25TH 2026 Disclaimer The material contained in this document is a presentation of general background information on to identify forward-looking statements. These forward-looking statements reflect Imricor’s current Imricor Medical Systems, Inc. (Imricor) and its activities current as of the
Slide 3: Delivering key milestones in 2025
FEBRUARY 25TH 2026 Delivering key milestones in 2025 Regulatory & Clinical Commercial Financial • CE Mark approval under MDR for 2nd generation • Completed integration and testing of NorthStar on • Revenue of US$292k temporarily impacted by ablation catheter and capital equipment Philips MRI platfor
Slide 4: Imricor is moving cardiac ablations from X-Ray to MRI Cath Labs
FEBRUARY 25TH 2026 Imricor is moving cardiac ablations From X-Ray Cath Labs To MRI Cath Labs • Boston Scientific • AtriCure 100% of consumable revenue captured • Johnson&Johnson MedTech • Kardium • Abbott • Medtronic IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 5: Imricor's solution – adding value to all stakeholders
FEBRUARY 25TH 2026 Imricor’s solution – adding value to all stakeholders Patient Doctor Payer Hospital • Higher single procedure success rates • Improved visualisation of heart • Similar or lower per-procedure costs • Similar cost to set up an iCMR EP lab achieved in clinical trials for AFL anatomy
Slide 6: Regulatory process is gaining momentum
FEBRUARY 25TH 2026 Regulatory process is gaining momentum Geography Regulation Imricor Product Suite Pathway Status Details • NorthStar • Advantage-MR EP Recorder/Stimulator • Vision-MR Diagnostic Catheter 2.0 Med • Vision-MR Diagnostic Cable Full technology platform to perform real-time Europe • Vi
Slide 7: Board of directors strengthened to support growth and commercialisation
FEBRUARY 25TH 2026 Board of directors strengthened to support growth and commercialisation “Throughout my 30-year career at companies such as Medtronic and Johnson & Johnson MedTech, I have witnessed remarkable innovations that have reshaped the landscape of healthcare and improved millions of lives
Slide 8: Financial Performance
FEBRUARY 25TH 2026 Financial Performance IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 9: Profit and loss
FEBRUARY 25TH 2026 Profit and loss US$’000 FY25 FY24 Commentary Revenue 292 959 • Revenue decrease on prior comparative period (pcp) is the result of customer sites enrolling trial patients, a 3rd party Costs and non-R&D expenses (11,418) (8,643) capital sale in Europe and a consumable sale to new R
Slide 10: Balance sheet
FEBRUARY 25TH 2026 Balance sheet US$’000 Dec-25 Dec-24 Cash and cash equivalents 19,502 15,708 Commentary Marketable securities 21,278 - • Cash, cash equivalents, and marketable securities balances Accounts receivable 241 345 total $40.8 million Inventory 1,096 1,502 • Convertible note held at fair
Slide 11: Cash flow
FEBRUARY 25TH 2026 Cash flow US$’000 FY25 FY24 Commentary Net loss (25,319) (29,693) • Other non-cash adjustments were down vs. pcp primarily Other non-cash adjustments 6,339 14,889 due to decreases in the change in fair value charges. • Purchases of marketable securities were $21.3m Change in other
Slide 12: Looking ahead to 2026 & beyond
FEBRUARY 25TH 2026 Looking ahead to 2026 & beyond IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 13: A strong and growing market in cardiac ablation
FEBRUARY 25TH 2026 A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers Drivers of global catheter ablation market Electrophysiology Devices Market Size US$bn 40 35 15% CAGR Increased incidence of cardiac
Slide 14: Pipeline benefiting from investment in sales
FEBRUARY 25TH 2026 Pipeline benefiting from investment in sales European active pipeline is rebuilding Imricor’s products are currently approved in 31 countries, with 8 45 countries containing customer sites 40 Estimated over 1,500,000 ablation 35 procedures across the US, EU and Aus in 30 2026, wit
Slide 15: VISABL-AFL Clinical Trial Sites – Atrial Flutter sets the stage
FEBRUARY 25TH 2026 VISABL-AFL Clinical Trial Sites – Atrial Flutter sets the stage DR. AV KOLANDAIVELU DR. AJAY PILLAI DR. MARCO GÖTTE PROF. JUERG SCHWITTER Johns Hopkins University Virginia Commonwealth University Health Amsterdam University Medical Center MD, Director Cardiac MR Centre, University
Slide 16: Ventricular Tachycardia changes the game
FEBRUARY 25TH 2026 Ventricular Tachycardia changes the game VT & AF Limited soft tissue view ≈ $2,000 / case Left-sided access is required X-ray fluoroscopy can’t show the septum nor ICE adds guidance …. and cost the heart Most VT and AF ablations target the left side of With X-ray, soft tissue is l
Slide 17: Ventricular Tachycardia changes the game
FEBRUARY 25TH 2026 Ventricular Tachycardia changes the game Scar channels 3D mapping Catheters + time ≈ $2000 VT substrate is hard to find Hundreds of points per case Mapping adds cost and hours Scarring on the heart can form narrow channels With fluoroscopy blind to myocardium, Dedicated mapping ca
Slide 18: The Imricor solution
FEBRUARY 25TH 2026 The Imricor solution Full MRI of heart Shell creation & scar identification Targets ablated under real-time in NorthStar MRI imaging MRI used to cross the septum Shells created from the actual heart images Ablation under real-time MRI guidance No need for ICE catheter eliminates p
Slide 19: iCMR Lab Economics
iCMR Lab Economics FEBRUARY 25TH 2026 better outcomes, higher throughput, higher margins US Top 50 Hospitals by volume AFL VT Afib Total Average procedures pa 434 173 1010 1617 Imricor estimated ASP US$ per procedure $4000 $6500 $6500 Revenue opportunity per hospital for Imricor $1.7m $1.1m $6.6m $9
Slide 20: NorthStar – Cleared and ready for commercialisation
FEBRUARY 25TH 2026 NorthStar – Cleared and ready for commercialisation NorthStar Key piece of the infrastructure, intended to be the central hub of every iCMR lab Mapping System AI powered application potential well beyond cardiac ablation Strong in-bound interest from hospitals Solves problem for p
Slide 21: Several key value drivers during 2025/26
FEBRUARY 25TH 2026 Several key value drivers during 2025/26 FDA Approval for US commercial release of New site activations, growing installed base platform technology globally • 510(k) submissions / approvals • VISABL-AFL clinical trial expands in U.S. • PMA submissions / approvals Middle East first
Slide 22: Questions?
FEBRUARY 25TH 2026 Questions? IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 23: Appendix
FEBRUARY 25TH 2026 Appendix IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 24: A strong intellectual property portfolio
FEBRUARY 25TH 2026 A strong intellectual property portfolio Imricor’s patents protect technology that allows Imricor to manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. 19 issue
Slide 25: Imricor Leadership: Management
FEBRUARY 25TH 2026 Imricor Leadership: Management STEVE WEDAN GREG ENGLEHARDT NICK TWOHY JENNIFER WEISZ VIC FABANO President and Chief Executive Vice President of Global Sales Vice President of Marketing Vice President of Regulatory and Vice President of Operations Officer, and Board Chair and Busin
Slide 26: Imricor Leadership: Board of directors
FEBRUARY 25TH 2026 Imricor Leadership: Board of directors STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL JEFFREY LEIGHTON ALDO DENTI President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Non-executive Director Officer, and Boar
Slide 27: Key terms
FEBRUARY 25TH 2026 Key terms • Medical device developed by Imricor, designed for use within an MRI Vision-MR Ablation Catheter • World first, no competitors, all others only compatible with X-ray • Irregular heartbeat, affects approximately 2% of US population • Expected to double to 4% of US popula
Slide 28: Contact information
FEBRUARY 25TH 2026 Contact information Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.cork
Imricor Medical Systems — FY2025 Earnings Presentation on 6ix